Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Revlimid Offers Great Convenience: Dr Hatake of Cancer Institute Hospital
August 29, 2011
- US Court of Appeals Rules for MTPC in Argatroban Patent Dispute
August 29, 2011
- No. of Health Insurance Societies That Report Savings by Generics to Insured More Than Triples: Kenporen
August 29, 2011
- Launching of Novel Anticoagulants Welcomed: JCS Symposium
August 29, 2011
- Radioactive Cesium Detected from RDF Incineration Ashes at Chugai's Research Lab
August 29, 2011
- St. Marianna Univ. Hospital Group Saves over ¥600 Mil. in Drug Expenditures by Using Generics
August 29, 2011
- Takeda to Increase No. of MRs to 2,000 in China
August 29, 2011
- Concrete Disclosure Standards Should Have Been Included in JPMA's GLs for COI: Prof. Miyata
August 29, 2011
- Eisai Subsidiary's CT Colonography System Receives Approval in Japan
August 29, 2011
- Actos Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
August 29, 2011
- Korosho to Grant Subsidies to 4 Companies to Develop, Manufacture New Flu Vaccines
August 29, 2011
- Use Medicoeconomic Evaluation in NHI Drug Pricing: Korosho Study Group
August 29, 2011
- Novartis Pharma to Ask Korosho Why It Was Not Selected for Vaccine Grant
August 29, 2011
- Korosho Orders Revision of Package Insert, “Blue Letter”for Prazaxa after 5 Deaths
August 29, 2011
- NanoCarrier Ties Up with Kyoto Univ. for Nucleic Acid Drugs
August 29, 2011
- AZ Aims to Make Nexium the No. 1 PPI in Japan
August 29, 2011
- Celsentri Approved for Naive HIV-Infected Patients: ViiV Healthcare
August 29, 2011
- AnGes MG to Jointly Develop Therapeutic HPV Vaccine with GenoLac
August 29, 2011
- NBI Increasing Efforts to Ensure Proper Use of Prazaxa
August 29, 2011
- Remicade Obtains Approval for Partial Changes in Dosage for Crohn's Disease
August 29, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…